In this report, we examine what lies ahead for healthcare AI in the new year. In November, a newly-assembled FDA advisory ...

BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Diffuse Large B-Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The agreement involves the advancement of the allogeneic CAR-T cell therapy platform into clinical trials ... antigen (BCMA)-targeting CAR-natural killer T (NKT) cells for Phase I trials of multiple ...

INR:7823. crash cart arrangement Northeast Pharmaceutical Dandong Pharmaceutical was punished by Liaoning Food and Drug Administration for illegally sellin ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Cadrenal Therapeutics (CVKD) recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin ...

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the ... dubbed LAVA-1207, in a phase 1 trial for prostate-specific membrane antigen-positive metastatic castration ...